Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Cytk save search
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-23 (Crawled : 13:30) - biospace.com/
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -6.95%
cardio trial star phase 3
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Published: 2021-06-15 (Crawled : 12:00) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: -0.23%
H: 4.68%
C: 2.2%
heart phase 3 trial enroll
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MNDAdditional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS
Published: 2020-12-14 (Crawled : 15:00) - biospace.com/
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: -1.62%
H: 8.25%
C: 6.15%
phase 3 trial als symposium designation
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
Published: 2020-09-23 (Crawled : 09:33) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: -1.36%
H: 6.7%
C: 3.79%
phase 3 phase 1 phase 2
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Published: 2020-10-08 (Crawled : 09:33) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: -36.9%
H: 1.6%
C: -8.31%
results heart phase 3 trial topline
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.